Latest updates, webinars, and events from ProMab
Join ProMab Biotechnologies on August 19, 2026, for a live webinar on our integrated immuno-oncology platform — CAR-T, Super-NK, gene editing, bispecific antibodies, and mRNA-lipid nanoparticles.
Read moreJoin ProMab Biotechnologies on May 20, 2026, for a live mRNA-Lipid Nanoparticle (LNP) Technology Webinar with Liang Hu, Ph.D., exploring breakthroughs in protein expression, CAR-T engineering, and immunotherapy development.
Read moreJoin our upcoming webinar to explore how mRNA–Lipid Nanoparticles (mRNA-LNPs) are driving breakthroughs in protein expression, CAR-T cell engineering, and immunotherapy development.
Read moreProMab Biotechnologies offers cutting-edge contract services for cell therapy and immunotherapy. Join us at ASCO 2025 — visit booth #13141 to learn how our CRO services can accelerate your drug development and immunotherapy programs. See you at ASCO!
Read moreMeet with Promab at AACR: Join us from April 27th-April 30th at Booth #2921 to explore our comprehensive Antibody, mRNA-LNP and Immune Cell CRO Services.
Read moreJoin ProMab Biotechnologies on March 27, 2025, for an exclusive mRNA-Lipid Nanoparticle (LNP) Technology Webinar with Dr. Liang Hu, Ph.D.
Read moreJoin our speakers, Robert Berahovich, PhD and John Sienkiewicz, for an exclusive webinar where we will showcase the latest advancements in CAR-T and CAR-NK cell therapies.
Read moreVita Goblubovskaya, PhD, discusses advancements in mRNA-LNP technology, including bispecific antibodies and CAR technology
Read moreAACR Annual Meeting 2024. Come visit the ProMab team and learn about our new products & services at our booth and poster session.
Read moreASCO Annual Meeting 2019 Come visit the ProMab team and learn about our new products & services Booth
Read moreCAR-TCR Summit 2019 Come visit the ProMab team and learn about our new products & services Booth #50
Read moreInitially Launching a Novel, High-Affinity BCMA CAR Targeting NK Cell Development Candidate For Multiple Myeloma, With An Option
Read moreProMab has recently had our work published in JoVE on the real-time cytotoxicity assay (RTCA) that we use
Read moreThe 2019 novel coronavirus (2019-nCoV) is a new virus that causes respiratory illness in people and can spread
Read moreBERKELEY, Calif. & RICHMOND, Calif.–(BUSINESS WIRE)–Caribou Biosciences, Inc., a leading CRISPR genome editing company, and ProMab Biotechnologies
Read moreProMab’s humanized CD19 CAR-T platform is a CAR T-cell therapy approved for adults with treatment of relapsed and
Read moreProMab Biotechnologies is the world’s first CRO committed to improving human health with a focus on immunotherapy, specifically
Read moreInterested in learning more about Bispecific Antibody Engineering? ProMab will be hosting a webinar encompassing our Bispecific Antibody
Read moreDr. Vita Golubovskaya, Director of R&D at ProMab will be hosting a webinar with Agilent that incorporates some
Read more
